|
|
|
|
Phototherapy in Childhood
Childhood Email Password Remember me HomeGeneral Topics in Pediatric Sponsor D Scott Cunningham MD, PhD, MDLinx Technology Advances: Dorothy J.Schirf, MD, MDLinx Oncology Article Summary Click the title below to leave the MDLinx Network...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
Cephalon, Inc.and ImmuPharma PLC has announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the investigational medication Lupuzor for the treatment of...
|
|
|
Cephalon & Immupharma Sign
FRAZER, PA.and LONDON - Cephalon Inc. and ImmuPharma PLC, a European pharmaceutical company, announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. and ImmuPharma PLC , a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing Cephalon with an option to...
|
|
|
Cephalon options rights to lupus drug from ImmuPharma
Philadelphia Business Journal Related News Biopharmaceutical company Cephalon Inc.has purchased an option to buy the exclusive worldwide rights to an experimental Lupus treatment owned by ImmuPharma, the two companies said Tuesday....
|
|
|
Cephalon, ImmuPharma sign $15 mn pact for late- stage experimental Lupus medication
Cephalon, Inc and ImmuPharma PLC, a European pharmaceutical company, announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the investigational medication...
|
|
|
Cephalon & ImmuPharma Sign a $15M Option Agree
Description: FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. (NASDAQ:CEPH) and ImmuPharma PLC , a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing...
|
|
|
MedPredict's Rheumatology Panel Analyzes Rheumatoid Arthritis, Lupus and Gout Markets and Pipelines Following
- (NewsRx.com) -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in...
|
|
|
Cephalon Pays ImmuPharma $15M for Option to Lupus Drug
Cephaloninked an option agreement to obtain an exclusive, worldwide license to ImmuPharmas Lupuzor for the treatment of systemic lupus erythematosus.ImmuPharma is now conducting a large Phase IIb study of Lupuzor in patients in Europe and...
|
|
|
Cephalon Inc and ImmuPharma PLC execute option agreement for late-stage experimental lupus medication
Cephalon Inc (Nasdaq: CEPH), a biopharmaceutical company, reported on 25 November that it has entered into an option agreement to acquire an exclusive, worldwide licence to the investigational medication Lupuzor for the treatment of Systemic...
|
|
|
Cephalon Inc and ImmuPharma PLC execute option agreement for late-stage experimental lupus medication
(M2 EQUITYBITES via COMTEX) -- CEPH | Quote | Chart | News | PowerRating -- Cephalon Inc (Nasdaq: CEPH), a biopharmaceutical company, reported on 25 November that it has entered into an option agreement to acquire an exclusive, worldwide...
|
|
|
Cephalon & Immupharma Sign A $15 Million Option Agreement
FRAZER, PA.and LONDON - Cephalon Inc. and ImmuPharma PLC, a European pharmaceutical company, announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the...
|
|
|
Cephalon, ImmuPharma sign a $15 million option agreement
Cephalon, and ImmuPharma, a European pharmaceutical company, announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the investigational medication Lupuzor...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH - News) and ImmuPharma PLC (LSE: IMM - News), a European pharmaceutical company, today announced that the companies have signed an Option Agreement...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Under the terms of the option agreement, Cephalon will pay ImmuPharma a $15 million upfront option payment. If the Phase IIb studies are successful and if the option is...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
/PRNewswire-FirstCall/ -- Cephalon, Inc.and ImmuPharma PLC , a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license...
|
|
|
Cephalon (CEPH) and ImmuPharma Sign $15 Million Option Agreement for Late-Stage Experimental Lupus Medication
Cephalon, Inc.(Nasdaq: CEPH) and ImmuPharma PLC announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license to the investigational medication Lupuzor(TM) for the...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and ImmuPharma PLC (LSE: IMM), a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and ImmuPharma PLC (LSE: IMM), a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and ImmuPharma PLC (LSE: IMM), a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
FRAZER, Pa.and LONDON, Nov. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and ImmuPharma PLC (LSE: IMM), a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing...
|
|
|
Cephalon options rights to lupus drug from ImmuPharma
Biopharmaceutical company Cephalon Inc.has purchased an option to buy the exclusive worldwide rights to an experimental Lupus treatment owned by ImmuPharma, the two companies said Tuesday. The companies said Frazer, Pa.-based...
|
|
|
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
/PRNewswire-FirstCall/ -- Cephalon, Inc.and ImmuPharma PLC , a European pharmaceutical company, today announced that the companies have signed an Option Agreement providing Cephalon with an option to obtain an exclusive, worldwide license...
|
|
|
ImmuPharma soars after drug deal
Shares in ImmuPharma rose by 33 per cent after the company signed a lucrative agreement with an American biopharmaceutical company that could be worth as much as $500 million (327 million).Cephalon will pay the British company $15 million...
|
|
|
Option deal boosts ImmuPharma
US pharmaceutical group Cephalon is to pay drug discoverer ImmuPharma 10 million upfront for an option on its Lupuzor lupus treatment.The option deal gives Cephalon the right to obtain an exclusive worldwide licence for Lupuzor, which...
|
